Identification

Name
Duloxetine
Accession Number
DB00476  (APRD00060)
Type
Small Molecule
Groups
Approved
Description

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.

Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.

Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

Structure
Thumb
Synonyms
  • (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
  • (S)-duloxetine
External IDs
LY 248686 / LY-248686 / LY248686
Product Ingredients
IngredientUNIICASInChI Key
Duloxetine hydrochloride9044SC542W136434-34-9BFFSMCNJSOPUAY-LMOVPXPDSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act DuloxetineCapsule, delayed release30 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act DuloxetineCapsule, delayed release60 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
Auro-duloxetineCapsule, delayed release30 mgOralAuro Pharma Inc2016-05-02Not applicableCanada
Auro-duloxetineCapsule, delayed release60 mgOralAuro Pharma Inc2016-05-02Not applicableCanada
CymbaltaCapsule, delayed release30 mg/1OralRemedy Repack2013-04-102016-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-duloxetineCapsule, delayed release60 mgOralApotex Corporation2016-05-03Not applicableCanada
Apo-duloxetineCapsule, delayed release30 mgOralApotex Corporation2016-05-03Not applicableCanada
DuloxetineCapsule, delayed release30 mg/1OralTrigen Laboratories, Inc.2014-08-19Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralBlue Point Laboratories2014-03-14Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCardinal Health2013-12-23Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralRemedy Repack2014-01-302016-04-05Us
DuloxetineCapsule, delayed release30 mg/1OralAjanta Pharma Limited2016-12-06Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCadila Pharnmaceuticals2014-05-27Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCipla Limited2015-12-05Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralRemedy Repack2016-01-26Not applicableUs
International/Other Brands
Ariclaim / Dulane / Duzela / Xeristar / Yentreve
Categories
UNII
O5TNM5N07U
CAS number
116539-59-4
Weight
Average: 297.415
Monoisotopic: 297.118734925
Chemical Formula
C18H19NOS
InChI Key
ZEUITGRIYCTCEM-KRWDZBQOSA-N
InChI
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
IUPAC Name
methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine
SMILES
CNCC[[email protected]](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1

Pharmacology

Indication

For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.

Structured Indications
Pharmacodynamics

Duloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes). Known also as LY248686, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system.

Mechanism of action

Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
Absorption

Orally administered duloxetine hydrochloride is well absorbed.

Volume of distribution
  • 1640 L
Protein binding

Protein binding is greater than 90%.

Metabolism

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.

Route of elimination

Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.

Half life

12 hours (range 8-17 hours)

Clearance
Not Available
Toxicity

Oral, rat LD50: 491 mg/kg for males and 279 mg/kg for females. Symptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 1A2CYP1A2*6Not Available5090C>TEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Duloxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Duloxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Duloxetine.Experimental
AcarboseDuloxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
AcenocoumarolDuloxetine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Duloxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Duloxetine.Approved
Acetylsalicylic acidDuloxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Duloxetine.Investigational
AdrafinilDuloxetine may increase the tachycardic activities of Adrafinil.Withdrawn
AgmatineDuloxetine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Duloxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Duloxetine.Approved, Investigational
AlaproclateDuloxetine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideDuloxetine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinAldesleukin may increase the orthostatic hypotensive activities of Duloxetine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Duloxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Duloxetine.Approved, Illicit
AliskirenAliskiren may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Duloxetine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Almotriptan.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Duloxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Duloxetine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Duloxetine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Duloxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Duloxetine.Approved, Withdrawn
AmibegronDuloxetine may increase the tachycardic activities of Amibegron.Investigational
AmifostineAmifostine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmilorideAmiloride may increase the orthostatic hypotensive activities of Duloxetine.Approved
AmineptineDuloxetine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Duloxetine.Approved, Withdrawn
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.Approved, Investigational
AmitrazDuloxetine may increase the tachycardic activities of Amitraz.Vet Approved
AmitriptylineDuloxetine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Duloxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Duloxetine.Approved, Illicit
Amphotericin BAmphotericin B may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Duloxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Duloxetine.Approved
Amyl NitriteAmyl Nitrite may increase the orthostatic hypotensive activities of Duloxetine.Approved
AnisodamineDuloxetine may increase the tachycardic activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Duloxetine.Approved
ApomorphineApomorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ApraclonidineApraclonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Duloxetine.Approved
ArbutamineDuloxetine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolDuloxetine may increase the tachycardic activities of Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Duloxetine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Duloxetine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Duloxetine.Approved, Withdrawn
AtenololAtenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
AtomoxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Duloxetine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the orthostatic hypotensive activities of Duloxetine.Approved
AzithromycinThe metabolism of Duloxetine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Duloxetine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.Illicit
BarnidipineBarnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
BefunololDuloxetine may increase the tachycardic activities of Befunolol.Experimental
BenazeprilBenazepril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Duloxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Duloxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Duloxetine.Approved
BenzphetamineDuloxetine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Duloxetine.Approved
BepridilBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
BethanidineDuloxetine may decrease the antihypertensive activities of Bethanidine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Duloxetine.Approved
BezitramideBezitramide may increase the serotonergic activities of Duloxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Duloxetine is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
BitolterolDuloxetine may increase the tachycardic activities of Bitolterol.Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Duloxetine.Approved
BortezomibBortezomib may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BretyliumBretylium may increase the orthostatic hypotensive activities of Duloxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.Approved
BrimonidineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Duloxetine.Experimental
BromocriptineBromocriptine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Duloxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Duloxetine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Duloxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Duloxetine.Experimental, Investigational
BumetanideBumetanide may increase the orthostatic hypotensive activities of Duloxetine.Approved
BupivacaineBupivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Duloxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Duloxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Duloxetine can be increased when it is combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Duloxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Duloxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Duloxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Duloxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Duloxetine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Duloxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Duloxetine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Duloxetine.Approved
CaffeineThe metabolism of Duloxetine can be decreased when combined with Caffeine.Approved
CanagliflozinCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
Candesartan cilexetilCandesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Duloxetine.Investigational
CaptoprilCaptopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Duloxetine.Approved, Investigational
CarbetocinCarbetocin may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Duloxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Duloxetine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Duloxetine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Duloxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Duloxetine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
CelecoxibDuloxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Duloxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Duloxetine.Approved, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Duloxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Duloxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Duloxetine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Duloxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Duloxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Duloxetine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Duloxetine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Duloxetine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorproethazine.Experimental
ChlorpromazineChlorpromazine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
ChlorpropamideDuloxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the orthostatic hypotensive activities of Duloxetine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.Approved
CholecalciferolThe metabolism of Duloxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilCilazapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
CilnidipineCilnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Duloxetine.Approved
CimetidineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Duloxetine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Duloxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Duloxetine.Approved, Investigational
CirazolineDuloxetine may increase the tachycardic activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Duloxetine.Approved
ClemastineThe metabolism of Duloxetine can be decreased when combined with Clemastine.Approved
ClenbuterolDuloxetine may increase the tachycardic activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Duloxetine.Approved
ClobazamThe metabolism of Duloxetine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineClofarabine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Duloxetine.Investigational
ClomipramineDuloxetine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Duloxetine.Approved, Illicit
ClonidineClonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Duloxetine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Duloxetine.Approved, Illicit
ClorindioneDuloxetine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Duloxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Duloxetine.Approved
CobicistatThe serum concentration of Duloxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Duloxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Duloxetine.Approved, Illicit
ConivaptanConivaptan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Duloxetine.Approved
CyclobenzaprineDuloxetine may increase the serotonergic activities of Cyclobenzaprine.Approved
CyclopenthiazideDuloxetine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.Approved, Investigational
CyproheptadineThe therapeutic efficacy of Duloxetine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Duloxetine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.Approved
DapagliflozinDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Duloxetine.Approved, Investigational
DarunavirThe serum concentration of Duloxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Duloxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Duloxetine.Approved, Investigational
DeferasiroxThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Duloxetine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Duloxetine.Investigational
DesfluraneDesflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DesipramineDuloxetine may increase the serotonergic activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Duloxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.Approved
DetomidineDuloxetine may increase the tachycardic activities of Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Duloxetine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Duloxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Duloxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Duloxetine.Approved, Illicit
DextromethorphanDuloxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Duloxetine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Duloxetine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Duloxetine.Approved, Illicit, Vet Approved
DibenzepinDuloxetine may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideDiclofenamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DicoumarolDuloxetine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Duloxetine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Duloxetine.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DiltiazemDiltiazem may increase the orthostatic hypotensive activities of Duloxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Duloxetine.Approved
DinutuximabDinutuximab may increase the orthostatic hypotensive activities of Duloxetine.Approved
DiphenadioneDuloxetine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Duloxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Duloxetine.Approved, Illicit
DipivefrinDuloxetine may increase the tachycardic activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.Approved
DisopyramideDuloxetine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dixyrazine.Experimental
DobutamineDuloxetine may increase the tachycardic activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Duloxetine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Duloxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Duloxetine.Approved
DopexamineDuloxetine may increase the tachycardic activities of Dopexamine.Investigational
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Duloxetine.Vet Approved
DosulepinDuloxetine may increase the serotonergic activities of Dosulepin.Approved
DoxazosinDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
DoxepinDuloxetine may increase the serotonergic activities of Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Duloxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Duloxetine.Approved, Investigational
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Duloxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Duloxetine.Investigational
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Duloxetine.Approved
DroperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Duloxetine.Experimental, Illicit
DroxidopaDuloxetine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DulaglutideDuloxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Duloxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.Approved, Investigational
EfonidipineEfonidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Duloxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Duloxetine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Duloxetine.Investigational
EmpagliflozinEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EnalaprilEnalapril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the orthostatic hypotensive activities of Duloxetine.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Duloxetine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Duloxetine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Duloxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Duloxetine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Duloxetine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Duloxetine.Experimental
EphedraDuloxetine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDuloxetine may increase the tachycardic activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Duloxetine.Approved, Investigational
EpinephrineDuloxetine may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
EplerenoneEplerenone may increase the orthostatic hypotensive activities of Duloxetine.Approved
EpoprostenolEpoprostenol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EprosartanEprosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Duloxetine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Duloxetine is combined with Escitalopram.Approved, Investigational
EsmirtazapineDuloxetine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Duloxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Duloxetine.Approved
Etacrynic acidEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Duloxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.Approved
Ethyl biscoumacetateDuloxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Duloxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Duloxetine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Duloxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Duloxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Duloxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Duloxetine.Investigational, Withdrawn
EtilefrineDuloxetine may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Duloxetine.Approved
EtodolacDuloxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateDuloxetine may decrease the antihypertensive activities of Etomidate.Approved
EtoricoxibDuloxetine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Duloxetine.Illicit, Vet Approved
ExenatideDuloxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Duloxetine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Duloxetine.Approved
FelodipineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineDuloxetine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamFenoldopam may increase the orthostatic hypotensive activities of Duloxetine.Approved
FenoterolDuloxetine may increase the tachycardic activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Duloxetine.Approved
FimasartanFimasartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Duloxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Duloxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Duloxetine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine.Approved, Illicit
FluindioneDuloxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Duloxetine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Duloxetine.Approved, Illicit
FluoxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Duloxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Duloxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Duloxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Duloxetine.Approved
FluvoxamineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolDuloxetine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Duloxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Duloxetine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Duloxetine.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Duloxetine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Duloxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Duloxetine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Duloxetine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Duloxetine.Investigational
GliclazideDuloxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDuloxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDuloxetine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Duloxetine.Approved, Illicit
GlyburideDuloxetine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Duloxetine.Approved, Investigational
GuanabenzDuloxetine may increase the tachycardic activities of Guanabenz.Approved, Investigational
GuanfacineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Duloxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Duloxetine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Duloxetine.Approved
HalothaneHalothane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Duloxetine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Duloxetine.Approved
HexoprenalineDuloxetine may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HigenamineDuloxetine may increase the tachycardic activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Duloxetine.Experimental
HydralazineHydralazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Duloxetine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Duloxetine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Duloxetine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Duloxetine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Duloxetine.Approved
IloprostIloprost may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Duloxetine.Approved
ImidaprilImidapril may increase the orthostatic hypotensive activities of Duloxetine.Investigational
ImipramineDuloxetine may increase the serotonergic activities of Imipramine.Approved
IndalpineDuloxetine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Duloxetine.Withdrawn
IndinavirThe metabolism of Duloxetine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Duloxetine.Investigational
IndoraminIndoramin may increase the orthostatic hypotensive activities of Duloxetine.Withdrawn
Insulin AspartDuloxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDuloxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDuloxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDuloxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDuloxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDuloxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Duloxetine.Approved, Investigational
Ioflupane I-123Duloxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.Approved
IprindoleDuloxetine may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the serotonergic activities of Duloxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Duloxetine.Withdrawn
IrbesartanIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the orthostatic hypotensive activities of Duloxetine.Approved
IsoetarineDuloxetine may increase the tachycardic activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
IsoniazidThe metabolism of Duloxetine can be decreased when combined with Isoniazid.Approved
IsoprenalineDuloxetine may increase the tachycardic activities of Isoprenaline.Approved
Isosorbide DinitrateIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
Isosorbide MononitrateIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
IsoxsuprineIsoxsuprine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
IsradipineIsradipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Duloxetine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Duloxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Duloxetine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Duloxetine.Approved, Investigational
KetoconazoleThe metabolism of Duloxetine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Duloxetine.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
LacidipineLacidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Duloxetine.Investigational
LercanidipineLercanidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Duloxetine.Approved, Investigational
LevobunololLevobunolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
LevobupivacaineLevobupivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Duloxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Duloxetine.Approved
LevodopaLevodopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Duloxetine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Duloxetine is combined with Levomilnacipran.Approved
LevonordefrinDuloxetine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Duloxetine.Approved
LevosimendanLevosimendan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Duloxetine.Approved
LidocaineThe metabolism of Duloxetine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Duloxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Duloxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Duloxetine.Approved
LiraglutideDuloxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilLisinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Duloxetine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Duloxetine.Approved
LobeglitazoneThe metabolism of Duloxetine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the serotonergic activities of Duloxetine.Illicit
LofepramineDuloxetine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineLofexidine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Duloxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Duloxetine.Approved
LopinavirThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Duloxetine.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Duloxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Duloxetine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Duloxetine.Approved
LosartanLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Loxapine.Approved
LumefantrineThe metabolism of Duloxetine can be decreased when combined with Lumefantrine.Approved
LumiracoxibDuloxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Duloxetine.Approved, Vet Approved
ManidipineThe metabolism of Duloxetine can be decreased when combined with Manidipine.Approved, Investigational
MannitolMannitol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Duloxetine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Duloxetine.Experimental
MecamylamineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
MecaserminDuloxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Duloxetine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Duloxetine.Experimental
MedetomidineDuloxetine may increase the tachycardic activities of Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Duloxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Melperone.Approved, Investigational
MephentermineDuloxetine may increase the tachycardic activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Duloxetine.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Duloxetine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Duloxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Duloxetine.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Duloxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Duloxetine.Approved, Investigational
MetaraminolDuloxetine may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine.Approved
MetforminDuloxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Duloxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Duloxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Duloxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Duloxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Duloxetine.Illicit, Withdrawn
MethazolamideMethazolamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Duloxetine.Approved
MethotrimeprazineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.Approved
MethoxamineDuloxetine may increase the tachycardic activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
MethoxyphenamineDuloxetine may increase the tachycardic activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.Approved
MethyclothiazideMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
MethyldopaMethyldopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Duloxetine.Experimental
Methylene blueDuloxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Duloxetine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Duloxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Duloxetine.Approved, Illicit, Withdrawn
MetipranololMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.Approved, Investigational
MetolazoneMetolazone may increase the orthostatic hypotensive activities of Duloxetine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Duloxetine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Duloxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Duloxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Duloxetine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.Approved, Illicit
MidodrineDuloxetine may increase the tachycardic activities of Midodrine.Approved
MifepristoneDuloxetine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolDuloxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Duloxetine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Duloxetine.Approved
MinoxidilMinoxidil may increase the orthostatic hypotensive activities of Duloxetine.Approved
MirabegronDuloxetine may increase the tachycardic activities of Mirabegron.Approved
MirtazapineDuloxetine may increase the serotonergic activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Moclobemide.Approved
MoexiprilMoexipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Moperone.Experimental
MorphineMorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Mosapramine.Experimental
MoxonidineMoxonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NabiloneNabilone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NabumetoneDuloxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Duloxetine.Approved
NaphazolineDuloxetine may increase the tachycardic activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Duloxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Nefazodone.Approved, Withdrawn
NesiritideNesiritide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Duloxetine.Approved
NevirapineThe metabolism of Duloxetine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Duloxetine.Withdrawn
NicardipineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Duloxetine.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Duloxetine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Duloxetine.Approved
NifedipineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NilotinibThe metabolism of Duloxetine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NimodipineNimodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NisoldipineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.Approved
NitrendipineNitrendipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
Nitric OxideNitric Oxide may increase the orthostatic hypotensive activities of Duloxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
NitroglycerinNitroglycerin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NitroprussideNitroprusside may increase the orthostatic hypotensive activities of Duloxetine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Duloxetine.Approved, Vet Approved
NorepinephrineDuloxetine may increase the tachycardic activities of Norepinephrine.Approved
NorfenefrineDuloxetine may increase the tachycardic activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Duloxetine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Duloxetine.Approved, Illicit
NortriptylineDuloxetine may increase the serotonergic activities of Nortriptyline.Approved
NylidrinDuloxetine may increase the tachycardic activities of Nylidrin.Approved
ObinutuzumabObinutuzumab may increase the orthostatic hypotensive activities of Duloxetine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Duloxetine.Withdrawn
OctopamineDuloxetine may increase the tachycardic activities of Octopamine.Experimental
OlanzapineDuloxetine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanOlmesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
OlodaterolDuloxetine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duloxetine.Approved
OndansetronOndansetron may increase the serotonergic activities of Duloxetine.Approved
OpipramolDuloxetine may increase the serotonergic activities of Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Duloxetine.Approved, Illicit
OrciprenalineDuloxetine may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Duloxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Duloxetine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Duloxetine.Approved, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Duloxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Duloxetine.Approved, Illicit, Investigational
OxyfedrineDuloxetine may increase the tachycardic activities of Oxyfedrine.Experimental
OxymetazolineDuloxetine may increase the tachycardic activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Oxypertine.Experimental
PaclitaxelPaclitaxel may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
PaliperidoneDuloxetine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Duloxetine.Approved, Investigational
PanobinostatThe serum concentration of Duloxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverinePapaverine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Duloxetine.Approved, Investigational
ParecoxibDuloxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Duloxetine.Approved
ParoxetineDuloxetine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Duloxetine.Approved
Peginterferon alfa-2bThe serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Duloxetine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Duloxetine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Duloxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perazine.Investigational
PergolideDuloxetine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Duloxetine.Approved, Investigational
PerindoprilPerindopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Duloxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Duloxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Duloxetine.Withdrawn
PhenazocinePhenazocine may increase the serotonergic activities of Duloxetine.Experimental
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Duloxetine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Duloxetine.Experimental
PhenindioneDuloxetine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Duloxetine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Duloxetine.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Duloxetine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Duloxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Duloxetine.Withdrawn
PhenprocoumonDuloxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolaminePhentolamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenylephrineDuloxetine may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineDuloxetine may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Duloxetine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pimozide.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
PioglitazoneDuloxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Duloxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Duloxetine.Approved, Investigational
PirbuterolDuloxetine may increase the tachycardic activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Duloxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Duloxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Duloxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Duloxetine.Approved
PolythiazideDuloxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Duloxetine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Duloxetine.Approved
PramipexolePramipexole may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
PramlintideDuloxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Duloxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine.Approved, Illicit
PrazosinPrazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Duloxetine.Approved, Illicit, Investigational
PrenalterolDuloxetine may increase the tachycardic activities of Prenalterol.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Duloxetine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Duloxetine.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Duloxetine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Duloxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Procarbazine.Approved
ProcaterolDuloxetine may increase the tachycardic activities of Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Duloxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Duloxetine.Approved, Vet Approved
PromazineThe metabolism of Duloxetine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Duloxetine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Duloxetine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Duloxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Propericiazine.Approved
PropofolPropofol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Duloxetine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prothipendyl.Investigational
ProtriptylineDuloxetine may increase the serotonergic activities of Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Duloxetine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Duloxetine.Investigational
PseudoephedrineDuloxetine may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Duloxetine.Approved, Illicit
QuetiapineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.Approved
QuinaprilQuinapril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
QuinethazoneDuloxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe serum concentration of Duloxetine can be increased when it is combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Duloxetine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Duloxetine.Experimental
RacepinephrineDuloxetine may increase the tachycardic activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Raclopride.Investigational
RactopamineDuloxetine may increase the tachycardic activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.Approved, Investigational
RamiprilRamipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Duloxetine.Approved
RanolazineThe metabolism of Duloxetine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the orthostatic hypotensive activities of Duloxetine.Approved
RemifentanilRemifentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Duloxetine.Approved, Withdrawn
RepaglinideDuloxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Duloxetine.Investigational
ReproterolDuloxetine may increase the tachycardic activities of Reproterol.Investigational
ReserpineReserpine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
RilmenidineDuloxetine may increase the tachycardic activities of Rilmenidine.Investigational
RimiterolDuloxetine may increase the tachycardic activities of Rimiterol.Experimental
RiociguatRiociguat may increase the orthostatic hypotensive activities of Duloxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Duloxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ritanserin.Investigational
RitobegronDuloxetine may increase the tachycardic activities of Ritobegron.Investigational
RitodrineDuloxetine may increase the tachycardic activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Duloxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Rizatriptan.Approved
RofecoxibDuloxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Duloxetine can be decreased when combined with Rolapitant.Approved
RomifidineDuloxetine may increase the tachycardic activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
RopivacaineRopivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved
RosiglitazoneDuloxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineRotigotine may increase the orthostatic hypotensive activities of Duloxetine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Duloxetine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Duloxetine.Approved
SacubitrilSacubitril may increase the orthostatic hypotensive activities of Duloxetine.Approved
SafrazineSafrazine may increase the serotonergic activities of Duloxetine.Withdrawn
SalbutamolDuloxetine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolDuloxetine may increase the tachycardic activities of Salmeterol.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Duloxetine.Approved, Investigational
SaxagliptinDuloxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine.Approved, Vet Approved
SelegilineSelegiline may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Duloxetine.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Duloxetine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Duloxetine.Approved, Investigational
SimeprevirThe metabolism of Duloxetine can be decreased when combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Duloxetine.Approved
SitagliptinDuloxetine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium NitriteSodium Nitrite may increase the orthostatic hypotensive activities of Duloxetine.Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Duloxetine.Approved
SolabegronDuloxetine may increase the tachycardic activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Duloxetine.Experimental
SpironolactoneSpironolactone may increase the orthostatic hypotensive activities of Duloxetine.Approved
StiripentolThe serum concentration of Duloxetine can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
SufentanilSufentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
SulfadiazineDuloxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleDuloxetine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleDuloxetine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sumatriptan.Approved, Investigational
SunitinibDuloxetine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Duloxetine.Approved
SynephrineDuloxetine may increase the tachycardic activities of Synephrine.Experimental
TalinololThe serum concentration of Talinolol can be increased when it is combined with Duloxetine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Duloxetine resulting in a loss in efficacy.Approved
TamsulosinTamsulosin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Duloxetine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Duloxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Duloxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Duloxetine.Investigational, Withdrawn
TelmisartanTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Duloxetine.Approved
Tenofovir disoproxilThe metabolism of Duloxetine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
TerbinafineThe serum concentration of Duloxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineDuloxetine may increase the tachycardic activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Duloxetine.Withdrawn
TeriflunomideThe serum concentration of Duloxetine can be decreased when it is combined with Teriflunomide.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Duloxetine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Duloxetine.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Duloxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Duloxetine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Duloxetine.Investigational
ThalidomideThalidomide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Duloxetine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Duloxetine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Duloxetine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thioproperazine.Approved
ThioridazineThioridazine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Duloxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Duloxetine.Approved
TianeptineDuloxetine may increase the serotonergic activities of Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Duloxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Duloxetine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Duloxetine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
TioclomarolDuloxetine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Duloxetine.Approved
TipranavirThe serum concentration of Duloxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
TolazamideDuloxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
TolbutamideDuloxetine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeTolcapone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Duloxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Duloxetine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Duloxetine.Approved
TorasemideTorasemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Duloxetine.Approved, Investigational
TramadolDuloxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilTrandolapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Duloxetine.Experimental
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Duloxetine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trazodone.Approved, Investigational
TretinoinTretinoin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Nutraceutical
TretoquinolDuloxetine may increase the tachycardic activities of Tretoquinol.Experimental
TriamtereneTriamterene may increase the orthostatic hypotensive activities of Duloxetine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Duloxetine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Duloxetine.Vet Approved
TrichlormethiazideDuloxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Duloxetine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineDuloxetine may increase the serotonergic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Duloxetine.Approved
TropisetronTropisetron may increase the serotonergic activities of Duloxetine.Approved, Investigational
TulobuterolDuloxetine may increase the tachycardic activities of Tulobuterol.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Duloxetine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Duloxetine.Approved, Investigational
ValdecoxibDuloxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Duloxetine.Approved, Investigational
ValsartanValsartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
VemurafenibThe serum concentration of Duloxetine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Duloxetine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Veralipride.Experimental
VerapamilVerapamil may increase the orthostatic hypotensive activities of Duloxetine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Duloxetine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Duloxetine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Vilazodone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Duloxetine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Duloxetine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Duloxetine.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Vortioxetine.Approved
WarfarinDuloxetine may increase the anticoagulant activities of Warfarin.Approved
XamoterolDuloxetine may increase the tachycardic activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Duloxetine.Experimental
XylazineDuloxetine may increase the tachycardic activities of Xylazine.Vet Approved
XylometazolineDuloxetine may decrease the antihypertensive activities of Xylometazoline.Approved
YM-178Duloxetine may increase the tachycardic activities of YM-178.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Duloxetine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Duloxetine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Duloxetine.Approved
ZimelidineDuloxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Duloxetine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Duloxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Duloxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Duloxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Duloxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Duloxetine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.Approved, Investigational
Food Interactions
  • Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%.
  • People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity.
  • Take without regard to meals.

References

Synthesis Reference

Richard A. Berglund, "Intermediate useful for the asymmetric synthesis of duloxetine." U.S. Patent US5491243, issued June, 1991.

US5491243
General References
  1. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P: Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21. [PubMed:11282251]
  2. Anttila S, Leinonen E: Duloxetine Eli Lilly. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21. [PubMed:12211418]
  3. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192]
  4. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100]
  5. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838]
  6. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
External Links
Human Metabolome Database
HMDB14619
KEGG Drug
D01179
PubChem Compound
60835
PubChem Substance
46507937
ChemSpider
54822
BindingDB
84745
ChEBI
36795
ChEMBL
CHEMBL1175
Therapeutic Targets Database
DAP000494
PharmGKB
PA10066
IUPHAR
202
Guide to Pharmacology
GtP Drug Page
HET
29E
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Duloxetine
ATC Codes
N06AX21 — Duloxetine
AHFS Codes
  • 28:16.04.16 — Selective Serotonin and Norepinephrine-reuptake Inhibitors
PDB Entries
4mm6 / 4mmd
FDA label
Download (104 KB)
MSDS
Download (76.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePosttraumatic Stress Disorders1
0CompletedBasic ScienceStrokes1
1CompletedNot AvailableDrug-Drug Interaction (DDI)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceAmphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders1
1CompletedBasic ScienceAnticoagulant Effect of Warfarin When Taken With Duloxetine1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers / Hyperalgesia1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1RecruitingBasic ScienceCocaine Use Disorders1
1RecruitingOtherMajor Depressive Disorder (MDD)1
1, 2Active Not RecruitingTreatmentOsteoarthritis Of Knee1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentDepressive State2
2CompletedTreatmentDiabetic Neuropathies / Diabetic Neuropathy, Painful / Diabetic Polyneuropathy / Neuralgia, Diabetic1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Peripheral Neuropathy1
2CompletedTreatmentMajor Depressive Disorder (MDD)4
2CompletedTreatmentPain, Neuropathic / Peripheral Neuropathy1
2CompletedTreatmentUrinary Incontinence (UI)1
2CompletedTreatmentUrinary Stress Incontinence2
2Not Yet RecruitingTreatmentParkinson's Disease (PD)1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentGulf War Illness1
2RecruitingTreatmentPain1
2TerminatedTreatmentDepressive State / Traumatic Brain Injury (TBI)1
2TerminatedTreatmentDiabetic Neuropathic Pain1
2TerminatedTreatmentMajor Depressive Disorder (MDD)2
2, 3CompletedTreatmentDiabetes Mellitus (DM) / Peripheral Neuropathy1
2, 3CompletedTreatmentDisseminated Sclerosis1
2, 3CompletedTreatmentFatigue Syndrome, Chronic1
2, 3RecruitingPreventionPostoperative Myalgia1
3Active Not RecruitingTreatmentCancer, Breast / Musculoskeletal Complications / Pain1
3Active Not RecruitingTreatmentFibromyalgia1
3Active Not RecruitingTreatmentMajor depressive disorder, recurrent episode1
3CompletedBasic ScienceParkinson's Disease (PD)1
3CompletedBasic SciencePost-gastrointestinal bypass surgery1
3CompletedSupportive CareNeurotoxicity / Pain / Peripheral Neuropathy / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAnxiety Disorders5
3CompletedTreatmentAnxiety States, Neurotic / Neuroses, Anxiety1
3CompletedTreatmentBack Pain Lower Back Chronic2
3CompletedTreatmentBack Pain Without Radiation2
3CompletedTreatmentChronic Low Back Pain (CLBP)1
3CompletedTreatmentCognition / Depressive State1
3CompletedTreatmentDepressive Disorder, Treatment-Resistant / Major depressive disorder, recurrent episode1
3CompletedTreatmentDepressive Disorders1
3CompletedTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepressive State1
3CompletedTreatmentDepressive State / Pain1
3CompletedTreatmentDiabetic Neuropathies3
3CompletedTreatmentDiabetic Neuropathy, Painful3
3CompletedTreatmentDisseminated Sclerosis1
3CompletedTreatmentFeeling Anxious1
3CompletedTreatmentFibromyalgia6
3CompletedTreatmentFibromyalgia / Infection, Human Immunodeficiency Virus I1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)2
3CompletedTreatmentMajor Depressive Disorder (MDD)18
3CompletedTreatmentOsteoarthritis Knee Pain4
3CompletedTreatmentOsteoarthritis of the Knees2
3CompletedTreatmentSphincter of Oddi Dysfunction1
3CompletedTreatmentStress Urinary Incontinence (SUI)2
3CompletedTreatmentUrinary Incontinence Stress1
3CompletedTreatmentUrinary Incontinence,Stress6
3CompletedTreatmentUrinary Stress Incontinence2
3CompletedTreatmentSynovitis of osteoarthritis1
3Not Yet RecruitingOtherMajor Depressive Disorder (MDD)1
3Not Yet RecruitingTreatmentDepressive Disorders1
3RecruitingTreatmentDepressive Disorder, Treatment-Resistant / Major depressive disorder, recurrent episode1
3RecruitingTreatmentMajor depressive disorder, recurrent episode2
3RecruitingTreatmentProstate Cancer / Urinary Incontinence (UI)1
3TerminatedPreventionDepressive State1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPosttraumatic Stress Disorders1
4Active Not RecruitingSupportive CareDepressive State / Mild Cognitive Impairment (MCI)1
4Active Not RecruitingSupportive CareIntervertebral Disc Degeneration1
4Active Not RecruitingTreatmentCryptogenic Sensory Polyneuropathy1
4Active Not RecruitingTreatmentPain, Chronic / Synovitis of osteoarthritis1
4CompletedBasic ScienceHealthy Participants / Major Depressive Disorder (MDD)1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceSynovitis of osteoarthritis1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedPreventionMigraines1
4CompletedTreatmentAgeing / Back Pain / Major Depressive Disorder (MDD)1
4CompletedTreatmentAtypical Depression1
4CompletedTreatmentBinge Eating / Depressive State1
4CompletedTreatmentChronic Low Back Pain (CLBP)1
4CompletedTreatmentChronic Primary Headache / Major Depressive Disorder (MDD)1
4CompletedTreatmentDementias / Depressive State1
4CompletedTreatmentDepressive Disorder NOS / Dysthymic Disorder1
4CompletedTreatmentDepressive Disorders1
4CompletedTreatmentDepressive State4
4CompletedTreatmentDepressive State / Dysthymic Disorder1
4CompletedTreatmentDepressive State / Menopause / Vasomotor Symptoms1
4CompletedTreatmentDiabetic Neuropathies1
4CompletedTreatmentDiabetic Neuropathy, Painful2
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain1
4CompletedTreatmentFibromyalgia1
4CompletedTreatmentFibromyalgia, Primary / Fibromyalgia, Secondary1
4CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
4CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Irritable Bowel Syndrome (IBS)1
4CompletedTreatmentIdiopathic Parkinson's Disease / Major Depressive Disorder (MDD)1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
4CompletedTreatmentIrritable Bowel Syndrome (IBS) / Irritable Bowel Syndrome Symptoms / Major Depressive Disorder (MDD)1
4CompletedTreatmentMajor Depressive Disorder (MDD)17
4CompletedTreatmentMajor Depressive Disorder (MDD) / Pain / Soft Tissue Discomfort Syndrome1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)1
4CompletedTreatmentPain / Synovitis of osteoarthritis1
4CompletedTreatmentPanic Disorders1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentStress Urinary Incontinence (SUI)1
4CompletedTreatmentTotal Knee Arthroplasty (TKA)1
4CompletedTreatmentUrinary Incontinence,Stress1
4Enrolling by InvitationTreatmentJoint Disease / Pain, Acute / Pain, Chronic1
4Not Yet RecruitingNot AvailablePain, Neuropathic1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
4RecruitingOtherDepressive State / Male Infertility1
4RecruitingTreatmentDepressive Disorder, NOS / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4RecruitingTreatmentDepressive State / Hard of Hearing1
4RecruitingTreatmentGynecologic Surgery / Laparoscopy / Quality of Recovery1
4SuspendedTreatmentDepressive State1
4TerminatedTreatmentChronic Low Back Pain (CLBP) / Diabetic Neuropathic Pain1
4TerminatedTreatmentDepressive State1
4TerminatedTreatmentFibromyalgia1
4TerminatedTreatmentPelvis Pain Chronic1
4Unknown StatusBasic ScienceMajor Depressive Disorder (MDD)1
4Unknown StatusDiagnosticSchizophrenic Disorders1
4Unknown StatusTreatmentBereavement / Depressive State1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)2
4WithdrawnTreatmentDiabetic Polyneuropathy / Postherpetic Neuralgia1
4WithdrawnTreatmentFibromyalgia1
Not AvailableActive Not RecruitingNot AvailableAnxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingBasic ScienceHealthy Volunteers1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depressive State1
Not AvailableCompletedNot AvailableObsessive Compulsive Disorder (OCD)1
Not AvailableCompletedNot AvailablePain2
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedHealth Services ResearchMajor Depressive Disorder (MDD)1
Not AvailableCompletedPreventionPain1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentDepressive Disorders1
Not AvailableCompletedTreatmentDepressive State1
Not AvailableCompletedTreatmentDiabetes / Painful Neuropathy1
Not AvailableCompletedTreatmentFunction Improvement / Pain Reduction1
Not AvailableCompletedTreatmentLow Back Pain (LBP)1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)2
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentTemporomandibular Joint Disorders1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNo Longer AvailableNot AvailableDiabetic Peripheral Neuropathic Pain / Fibromyalgia / Generalized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
Not AvailableNot Yet RecruitingTreatmentFibromyalgia / Hyperbaric Oxygen1
Not AvailableNot Yet RecruitingTreatmentPain, Neuropathic1
Not AvailableNot Yet RecruitingTreatmentSynovitis of osteoarthritis1
Not AvailableRecruitingNot AvailableAdhd / Anorexia Nervosa (AN) / Depressive State1
Not AvailableRecruitingNot AvailablePregnancy1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentAntidepressant Drug Adverse Reaction / Depressive State1
Not AvailableRecruitingTreatmentMigraines1
Not AvailableTerminatedNot AvailableChronic Phantom Limb Pain1
Not AvailableTerminatedBasic ScienceFeeling Anxious / Worrying1
Not AvailableTerminatedTreatmentChronic Pain, Postoperative1
Not AvailableTerminatedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusBasic ScienceChronic Depression1
Not AvailableUnknown StatusTreatmentFibromyalgia2
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnTreatmentMajor Depressive Disorder (MDD) / Postpartum Depression1
Not AvailableWithdrawnTreatmentObsessive Compulsive Disorder (OCD)1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral30 mg
Capsule, delayed releaseOral60 mg
Capsule, delayed releaseOral30 mg/1
Capsule, delayed releaseOral60 mg/1
Capsule, delayed releaseOral20 mg/1
Capsule, delayed release pelletsOral30 mg/1
Capsule, delayed release pelletsOral60 mg/1
Capsule, delayed release pelletsOral20 mg/1
Capsule, delayed releaseOral40 mg/1
Capsule, delayed releaseOral20 mg
Capsule, delayed releaseOral40 mg
Prices
Unit descriptionCostUnit
Cymbalta 30 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 60 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 30 mg capsule5.18USD capsule
Cymbalta 60 mg capsule5.18USD capsule
Cymbalta 20 mg Enteric Coated Capsule4.64USD capsule
Cymbalta 20 mg capsule4.62USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5023269No1993-06-112013-06-11Us
CA2344057No2008-11-182019-09-10Canada
CA2153856No2005-05-102015-07-13Canada
US6596756Yes2000-03-102020-03-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00296 mg/mLALOGPS
logP4.72ALOGPS
logP4.2ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)9.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.73 m3·mol-1ChemAxon
Polarizability33.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9804
Caco-2 permeable+0.6358
P-glycoprotein substrateSubstrate0.7078
P-glycoprotein inhibitor IInhibitor0.5987
P-glycoprotein inhibitor IINon-inhibitor0.5519
Renal organic cation transporterInhibitor0.6525
CYP450 2C9 substrateNon-substrate0.5964
CYP450 2D6 substrateSubstrate0.6482
CYP450 3A4 substrateSubstrate0.5799
CYP450 1A2 substrateInhibitor0.839
CYP450 2C9 inhibitorNon-inhibitor0.7721
CYP450 2D6 inhibitorInhibitor0.6977
CYP450 2C19 inhibitorNon-inhibitor0.572
CYP450 3A4 inhibitorInhibitor0.5108
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6689
Ames testNon AMES toxic0.5422
CarcinogenicityNon-carcinogens0.9293
BiodegradationNot ready biodegradable0.935
Rat acute toxicity2.5700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5926
hERG inhibition (predictor II)Inhibitor0.6386
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0890000000-a1b4d59cc0496fb3b755
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0970000000-5a3d39a5afda39a4ec23
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0590000000-894e0be7451e63140e89

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Aralkylamines / Alkyl aryl ethers / Thiophenes / Heteroaromatic compounds / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Naphthalene / Alkyl aryl ether / Aralkylamine / Thiophene / Heteroaromatic compound / Secondary aliphatic amine / Ether / Secondary amine / Organoheterocyclic compound / Organooxygen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
duloxetine (CHEBI:36795)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064]
  2. Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29. [PubMed:16032412]
  3. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830]
  4. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951]
  5. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476]
  6. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506]
  7. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192]
  8. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100]
  9. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838]
  10. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530]
  11. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657]
  12. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324]
  13. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
  14. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476]
  4. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506]
  5. Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7. [PubMed:15184278]
  6. Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H: Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol. 2005 Oct;15(5):517-20. Epub 2005 Apr 7. [PubMed:16139169]
  7. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951]
  8. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192]
  9. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100]
  10. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838]
  11. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530]
  12. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657]
  13. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324]
  14. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
  15. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
  4. Pereira P, Gianesini J, da Silva Barbosa C, Cassol GF, Von Borowski RG, Kahl VF, Cappelari SE, Picada JN: Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models. Pharmacol Res. 2009 Jan;59(1):57-61. doi: 10.1016/j.phrs.2008.09.014. Epub 2008 Oct 5. [PubMed:18973814]
  5. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359]
  2. Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP: In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191-202. [PubMed:18307373]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
Details
2. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359]
  2. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ: Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008 Nov;14(6):368-78. doi: 10.1097/01.pra.0000341891.43501.6b. [PubMed:19057238]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49